| scholarly article | Q13442814 |
| P50 | author | Josef Mautner | Q87626502 |
| Georg W Bornkamm | Q94069890 | ||
| P2093 | author name string | Uta Behrends | |
| Dinesh Adhikary | |||
| Klaus Witter | |||
| Stefanie Linnerbauer | |||
| P2860 | cites work | EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency. | Q53511676 |
| Transfer of a functional human immune system to mice with severe combined immunodeficiency | Q59071673 | ||
| Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma | Q70467906 | ||
| Adoptive immunotherapy for EBV-associated malignancies | Q81204067 | ||
| Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease | Q36399791 | ||
| Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. | Q36766875 | ||
| Phenotype and function of human T lymphocyte subsets: consensus and issues | Q37266382 | ||
| Immune defence against EBV and EBV-associated disease | Q37832581 | ||
| Immunotherapy for EBV-associated malignancies. | Q37845178 | ||
| Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses | Q39607047 | ||
| Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors | Q39715560 | ||
| CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells | Q39851225 | ||
| Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease | Q39876410 | ||
| CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines | Q40441967 | ||
| Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells | Q40526255 | ||
| Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy | Q40649977 | ||
| Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease | Q41355210 | ||
| Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man | Q41704288 | ||
| Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition | Q42066029 | ||
| Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles | Q42221268 | ||
| Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model | Q42564555 | ||
| Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells | Q44013424 | ||
| Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation | Q44618759 | ||
| Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. | Q44968633 | ||
| Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. | Q45741073 | ||
| Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. | Q45754081 | ||
| Activity of transplanted CD8+ versus CD4+ cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice. | Q45783101 | ||
| T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice | Q45789448 | ||
| The history of tumor virology | Q24610004 | ||
| Two subsets of memory T lymphocytes with distinct homing potentials and effector functions | Q28146072 | ||
| Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. | Q30442797 | ||
| Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy | Q33289956 | ||
| Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. | Q33713932 | ||
| Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells | Q33831940 | ||
| Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders | Q34121679 | ||
| Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines | Q34123922 | ||
| Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model | Q34123985 | ||
| Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation | Q34312922 | ||
| Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects | Q34374139 | ||
| Translating tumor antigens into cancer vaccines | Q34484042 | ||
| Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial | Q34623991 | ||
| A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation | Q35012553 | ||
| Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach | Q35139240 | ||
| EBV-induced human B cell lymphomas in hu-PBL-SCID mice | Q35232515 | ||
| Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer. | Q35402927 | ||
| Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. | Q35829364 | ||
| The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators | Q36079854 | ||
| Epstein Barr virus-associated tumours: an update for the attention of the working pathologist | Q36172481 | ||
| Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. | Q36228567 | ||
| Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice | Q36365868 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymphoproliferative disorders | Q4165484 |
| P304 | page(s) | e1004068 | |
| P577 | publication date | 2014-05-22 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders | |
| P478 | volume | 10 |
| Q26782845 | Adoptive T-Cell Immunotherapy |
| Q91142437 | Defective Epstein-Barr virus in chronic active infection and haematological malignancy |
| Q55057118 | Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Against Immunodominant Lytic and Latent EBV Antigens in Children With Primary EBV Infection. |
| Q54266087 | Human γ-Herpesvirus Infection, Tumorigenesis, and Immune Control in Mice with Reconstituted Human Immune System Components. |
| Q92151588 | Immune Control and Vaccination against the Epstein-Barr Virus in Humanized Mice |
| Q38587362 | Immune control of oncogenic γ-herpesviruses |
| Q60306812 | Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice |
| Q47195330 | Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses |
| Q89587166 | Tumor Microenvironment Conditioning by Abortive Lytic Replication of Oncogenic γ-Herpesviruses |
Search more.